Monk BJ, Herzog TJ, Wang G, et al. - Among women who received treatment for platinum-sensitive, recurrent ovarian cancer, researchers compared overall survival (OS) between those managed with third-line trabectedin (T) + pegylated liposomal doxorubicin (PLD) vs PLD monotherapy, in this phase 3 study. Random allocation (1: 1) of women with advanced-relapsed epithelial ovarian cancer (n = 576) to intravenous infusions of either T + PLD (trabectedin 1.1 mg/m² for 3 h; PLD 30 mg/m² for 1.5 h, every 3 weeks) (n = 289) or PLD (50 mg/m² for 1.5 h, every 4 weeks) (n = 287) was done. Findings revealed that neither favorable OS benefit nor safety was shown by the combination of T and PLD; however, T + PLD seemed to provide a clinically relevant survival benefit in patients with germline BRCA1/2 mutations and/or a platinum-free interval of 6–12 months. No new safety signals were reported.